ORKA
Oruka Therapeutics, Inc.
A clinical-stage biotech developing longer-lasting antibody drugs for skin conditions like psoriasis, aiming for injections that may be needed only once or twice a year. Its lead candidates, ORKA-001 and ORKA-002, come from Paragon Therapeutics, a drug-discovery engine that also spawned other biotechs. The name blends Hebrew words for "skin" and "restoration," and the company went public in 2024 through a reverse merger with ARCA biopharma, trading as "ORKA."
CUSIP: 687604108HealthcareUS1 holder
Recent Activity
2026Q2
1 sell
-1.16M shares(-43.6%)
-1.16M shares(-43.6%)
Loading more activity...